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Abstract 
Background/Aims The natural history of thyroid function in  children with Down 
syndrome (DS) is relatively unknown We hypothesized that in these patients the occurrence 
of thyroid dysfunction rises during development. 
Methods - Thyroid function was assessed yearly in 145 children with DS, all followed from 
birth up to 10 years of age. Heteroskedastic binary and ordinary logistic regression for 
repeated measures were used to evaluate the relationship of thyroid function with continuous 
time. 
Results - Congenital hypothyroidism was detected in 7% of cases. The probability of 
acquired thyroid dysfunction increased from 30% at birth to 49% at 10 years (p<0.001). The 
subclinical hypothyroidism (S-HT) was nearly stable during the follow-up. The probability of 
hypothyroidism increased from 7% to 24% at 10 years (p<0.001). Positive anti-thyroglobulin 
antibodies were associated with a higher odds of more severe hypothyroidism [odds ratio 
(OR)=3.6]. Positive anti-thyroid peroxidase antibodies (TPOab) were a better predictor of 
more severe hypothyroidism, (OR=6.1). Diffuse hypoechogenicity on thyroid ultrasound was 
found in 34 out of 145 children.  
Conclusion - The probability of thyroid dysfunction increases during development is higher 
than previously reported. Such children should be carefully monitored annually to early 
identify thyroid dysfunction. 
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Introduction 
Down's syndrome (DS), the most common chromosomal disorder, is associated with 
several concomitant diseases, including thyroid dysfunction [1-3]. Thyroid disorders are more 
common in patients with DS than in the general population and they have been estimated to 
range between 4% and 19.5% [4-8] with an increase in frequency, up to 54%, as the children 
age [5, 9-10]. These abnormalities include congenital hypothyroidism (1–3.6%) [7, 11-14], 
primary hypothyroidism (0.3-3.2%) [7, 14-15], autoimmune thyroiditis (0.3–1.4%) [16], and 
subclinical hypothyroidism (12.5–32.9%) [7, 10, 14-15, 17]. In addition,  hyperthyroidism (0–
2%) occurs in children with DS as well [7, 10, 18]. 
Pathogenesis, natural course, prognostic factors, and therapy of thyroid dysfunction in 
children with DS remain the objects of debate in the literature because epidemiological and 
long-term cohort studies are scarce. Pediatric endocrinologists frequently face the decision of 
what to do regarding these subjects. 
In the general population the natural history of Hashimoto’s thyroiditis in children and 
adolescents is not yet fully known. Thyroid-stimulating hormone concentrations showed large 
fluctuations over time, and a trend toward progressively deteriorating thyroid function was 
demonstrated [19-20]. A recent review on subclinical hypothyroidism in children showed that 
it is a remitting process with a rate of evolution toward overt hypothyroidism ranging between 
0 and 28.8% [21]. 
We hypothesized that the occurrence of thyroid diseases in children with DS rises in 
the course of development. Therefore, we investigated the probability of each thyroid disease 
in a cohort of 145 children with DS from birth to 10 years of age. 
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Subjects and methods 
Clinical and biochemical assessment.  
We conducted a cohort study from 1995 to 2010 including 205 Caucasian neonates 
with DS (95.6% with primary trisomy 21, 3.4% with translocation, and 1% with mosaicism) 
assessed at the Department of Pediatrics of the University of Modena and Reggio Emilia, 
Italy. Twenty neonates were not recruited because the parents refused the study, while during 
the follow-up children were excluded because of the development of severe heart disease in 
18 cases, leukemia in 4, seizure in 3, and coeliac disease in 10. We include this description of 
these subjects to avoid the lost to follow-up because of sudden death [22] and the diagnostic 
bias due to other exposure status. Specifically, patients with known autoimmune diseases [23] 
or using drugs that may interfere with thyroid function [24-25] are prone to develop 
autoimmune thyroiditis or subclinical hypothyroidism. Furthermore, 2 subjects refused to 
continue the study and 3 were lost to follow-up. Written informed consent was obtained from 
all parents at the moment of recruitment in the study and before the first data collection. The 
study was approved by the Ethics Committee of the University of Modena and Reggio Emilia. 
Thyroid function status was tested annually from birth over a 10-year period. Blood 
samples were analyzed for thyroid-stimulating hormone (TSH), free thyroxine (F-T4), 
thyroglobulin antibody (TGab), and thyroid peroxidase antibody (TPOab) within the same 
laboratory. Plasma TSH and F-T4 were measured by fluorometric assay (AutoDELFIA 
automatic immunoassay system). TGab and TPOab were quantified by an immunometric 
assay (IMMULITE 2000): values >40 IU/ml and >35 IU/ml were defined as positive, 
respectively. Ultrasonography of thyroid gland was performed by an experienced pediatric 
radiologist who was blinded to the thyroid status of the subjects. In subjects with congenital 
hypothyroidism (C-HT) it was immediately performed while in the other ones it was 
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firstly done at 2 years of age and repeated at time of thyroid dysfunction and/or thyroid 
autoantibodies development. In these cases a 2-year thyroid ultrasound follow-up was 
performed.   
 After exclusion of children with confirmed C-HT (newborn screening based on the 
measurement of TSH ≥ 20 μIU/ml on eluates of dry blood collected on filter paper after 24 h 
of life as the primary screening test and confirmed by plasma thyroid function test performed 
after 8 days of life), all DS children were annually grouped according to both F-T4 and TSH 
levels as: 
- euthyroidism (EuT): normal F-T4 and TSH ≤ 5 μIU/ml 
- hypothyroidism (HT): low F-T4 and TSH ≥ 10 μIU/ml 
- subclinical hypothyroidism (S-HT): normal F-T4 and TSH > 5 μIU/ml 
- hyperthyroidism (HyperT): high F-T4 and low TSH 
Children with C-HT were excluded from the present prospective analysis, but not at 
first year evaluation of thyroid dysfunction probability.  
Subjects with HT were treated with L-thyroxine and were considered in HT group 
during the whole follow up period. Replacement therapy was also started in children with S-
HT but only if TSH levels were persistently ≥ 10 μIU/ml [21] and these patients have always 
been included in the S-HT group. 
Statistical analysis 
Heteroskedastic binary and ordinal logistic regression for repeated measures were used 
to evaluate the changes of the binary and ordinal outcomes of interest with time [26-27]. 
These analyses were implemented using a heteroskedastic ordinal generalized linear model 
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(OGLM) with cluster confidence intervals to take into account repeated measures. The 
OGLM reduces to a logistic regression model when the outcome is binary and estimates the 
odds of more severe vs. less severe disease when the outcome is ordinal. The binary outcomes 
of interest were: 1) thyroid dysfunction (0 = no; 1 = yes), 2) TGab positivity (0 = no; 1 = yes), 
TPOab positivity (0 = no; 1 = yes). The ordinal outcome of interest was hypothyroidism (0 = 
EuT, 1 = S-HT and, 2 = overt HT). Time was modeled as continuous (years, 1 to 10 by steps 
of 1) and the possibility to control for heteroskedasticy was used to model non-linear time-
outcome relationships. To test whether TGab and TPOab are associated with hypothyroidism 
we added them, first separately and then together, with time as predictors of the logistic 
ordinal model (multivariable analysis). The odds ratio (OR) associated with TGab and TPOab 
is a time-averaged measure of their association with hypothyroidism. Statistical significance 
was set to a value of p<0.05. Statistical analysis was performed using STATA MP Version 
13.0. 
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Results 
 From 1995-2010, 145 of 205 patients with DS were longitudinally evaluated for the 
purpose of the study. Overall, 59% of the subjects were boys. 
During the first year of evaluation, C-HT was confirmed in 10 of 145 cases (6.9%; 6 
out 10 had thyroid agenesis, 2 had thyroid ectopia and, 2 had thyroid hypoplasia), 4 children 
had HT (2.7%; with normal thyroid ultrasound characteristics), 27 had S-HT (18.6%; 2 out of 
27 had thyroid hypoplasia and 1-year after developed thyroid autoantibodies), while the other 
104 had normal thyroid function. 
Figure 1 depicts the probability of any thyroid dysfunction during the study. Such 
probability increased from 30% (95%CI 24 to 37%) at 1
st
 year to 49% (41% to 58%) at 10
th
 
year (p<0.001, heteroskedastic binary logistic regression with cluster confidence intervals). 
Thyroid dysfunction was classified as HyperT in 1 case and as S-HT or overt HT in the 
remaining cases. Further analyses were performed on the subjects who did not develop 
HyperT.  
Figure 2 depicts the probability of EuT, S-HT and overt HT during the follow-up. The 
probability of EuT decreased from 71% (65% to 78%) at 1
st
 year to 52% (44% to 60%) at 10
th
 
year. S-HT had a fluctuating course between normal, compensated and overt HT so its 
probability was nearly stable, being 22% (17% to 28%) at 1
st
 year and 24% (17% to 31%) at 
10
th
 year. Lastly, the probability of overt HT increased from 7% (3% to 10%) at 1
st
 year to 
24% (17% to 32%) at 10
th
 year (p<0.001, heteroskedastic ordinal logistic regression with 
cluster confidence intervals). 
Considering the EuT group we found that, after 10 years, 64 patients still had normal 
function, 17 developed HT, and 22 developed S-HT. In the S-HT group one third developed 
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EuT at the end of the study without replacement therapy, while one third developed HT. The 
thyroid dysfunctions were almost equally distributed between the genders (data not show). 
Figures 3 and 4 depict the probability of positive thyroid autoantibodies (ATA) during 
the study. The probability of positive TGab increased from 3% (5‰ to 5%) at 1st year to 25% 
(17% to 33%) at 10
th
 year with corresponding figures of 5% (2% to 7%) and 37% (30% to 
45%) for TPOab (p<0.001, heteroskedastic binary logistic regression with cluster confidence 
intervals) (Figure 3). The significant increase in the probability of ATA was mainly found in 
subjects with EuT (32 out of 99 initially negative, 32.3%) and S-HT (14 out of 27 initially 
negative, 51.8%) (Figure 4).  
Combining the data according to thyroid function and the development of ATA, over a 
10-year period, we found two different natural course patterns for both EuT and S-HT, mainly 
depending on the presence or absence of ATA. In particular, 60% of ATA-positive EuT 
subjects developed a thyroid dysfunction, whereas 73% of ATA-negative EuT cases remained 
in EuT group (p=0.002). Among children with S-HT at first visit, 50% of ATA-positive cases 
had not changed at the last visit, whereas 28.6% developed HT. This prevalence was lower 
than in ATA-negative cases (38.5%); only 21.4% of ATA-positive subjects developed EuT, in 
contrast to the 46.1% we found among the ATA-negative cases (Figure 5).  
At multivariable ordinal logistic regression, TGab positivity was associated with an 
higher odds of more severe vs. less severe hypothyroidism but the estimate was imprecise 
(OR=3.6, 95%CI 1.2 to 11.0, p=0.02). On the contrary, TPOab positivity was strongly 
associated with more severe vs. less severe hypothyroidism (OR=6.1, 2.3 to 16.1, p<0.001). 
Adding TGab to TPOab was associated with no improvement in the prediction of the severity 
of hypothyroidism as compared to TPOab alone (OGLM not shown).  
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The characteristics of thyroid ultrasounds at the 10-year follow-up are reported in 
Table 1. Overall, 62% of subjects had normal echogenicity on ultrasound and 23.5% had 
diffuse hypoechogenicity (p<0.001). The prevalence of thyroid dysfunctions in children with 
hypoechogenicity was significantly higher than in individuals with normal thyroid 
echogenicity (61.8% vs. 37.8%; p=0.028). Considering ATA status we found that subjects 
with hypoechogenicity had a significantly higher percentage of ATA positivity than those 
with normal echogenicity (70.6 % vs. 31.0%; p<0.001). Interestingly, all subjects with diffuse 
hypoechogenicity on thyroid ultrasound but no circulating ATA (29.4%) had thyroid 
dysfunctions (6 S-HT and 4 HT) (Table 2).  
After exclusion of patients with C-HT, at the end of the follow-up 55 (41%) of our 
children were treated for thyroid disorders. Specifically, L-thyroxine replacement therapy was 
started in all children who developed HT and in 24 out of 31 (77.5%) patients with S-HT. 
Almost all patients with ATA-positive S-HT (88%) required treatment in contrast to the 64% 
of ATA-negative cases. Methimazole was used for the only child with HyperT.  
To assess the possibility that the level of initial TSH were predictive of a future 
thyroid dysfunction requiring L-thyroxine replacement therapy, we correlated the 1
st
 
year TSH values with the last ones before beginning of the treatment. Excluding data 
from the C-HT patients and the 4 subjects already having HT at 1-year of life, the TSH 
levels at 1
st
 year (4.92±1.83 IU/ml) and the ones just before therapy (12.3±13.5 IU/ml) 
were not significantly correlated (Spearman R=0.234, p=0.098). The same results were 
observed analyzing data according to 1
st
 year thyroid function: EuT (Spearman 
R=0.060, p=0.7322) and S-HT (Spearman R=0.317, p=0.230). Moreover, considering 
data from DS patients with S-HT at the end of the study, we found that both TSH 
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(Spearman R=-0.063, p=0.737) and FT4 (Spearman R=0.069, p=0.710) levels were not 
significantly correlated with BMI z-score. 
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Discussion 
 Several studies have investigated the prevalence of thyroid dysfunction in children and 
adults with DS [4, 10-12, 14-15, 28-29] but, to our best knowledge, this is the first 
prospective study to examine annually, over a 10-year period, the natural history of thyroid 
disorders in very young children with DS. Our data confirm the high probability of thyroid 
dysfunctions in children with DS, increasing year by year, when compared to reference ranges 
for the general population.  
In our cohort, C-HT probability was higher than reported in the literature, ranging 
from 1% to 2.7% [11-13]. Early thyroid screening increases the prevalence of newborns 
demonstrating a modest elevation of blood spot TSH concentrations due to the physiological 
neonatal surge, increasing the number of false-positive results. Newborns with DS generally 
have a mild hypothyroid state because of decreased thyroxine concentration that left-shifted 
normal distribution and mildly elevated TSH levels [30]. To avoid false-positive C-HT due to 
early measurement, we used a TSH screening cut-off of ≥ 20 μIU/ml and this allowed us to 
exclude additional cases of C-HT that were mainly due to functional disorders [31]. 
Moreover, to confirm the positive screening C-HT cases we adopted a diagnostic algorithm 
that included the subsequent confirmation by low plasma FT4, high TSH levels and thyroid 
ultrasound characteristics (6 agenesis, 2 ectopia, and 2 hypoplasia).  
Our children with DS suffered from two other different thyroid diseases such as S-HT 
mainly developed during the first 3 years of life and HT with a later onset; however, these 
thyroid dysfunctions were both present as early as the 1
st
 year of life. These cases of S-HT 
and HT, considering the thyroid ultrasound characteristics and the development of ATA, 
cannot be misdiagnosed with C-HT. Beyond the neonatal period, the incidence of elevated 
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TSH values in DS increases, being reported as high as 85% of infants under the age of 12 
months [32].  
Despite the limitation of the low number and the high heterogeneity of patients 
included in the published studies, in the general population S-HT is a benign and remitting 
process with a risk of progression to overt HT of approximately 0-12.5% [19, 21, 33-35]. In a 
retrospective multi-centre study [34], including a large pediatric cohort, it was demonstrated 
that TSH values tended to normalize proportionally to the degree of the TSH elevation at the 
initiation of the study. In subjects with TSH between 5.5 and 10 IU/ml, 73.6% normalized 
their TSH, about 25% maintained that range, and about 2% had their TSH increased over 10 
μIU/ml but with normal FT4. In subjects with initially highly elevated TSH, 40% normalized 
their TSH, 33.1% reduced their TSH to a value between 5.5 and 10 μIU/ml, 24.9% 
maintained their TSH higher than 10 μIU/ml. Overall, 70.1% of initially abnormal TSH levels 
normalize in the second evaluation while HT requiring replacement therapy was found in 
0.4% of the cohort.  
In our cohort we found that an increase in TSH levels such to support the definition of 
S-HT is not correlated with BMI z-score and may be considered a common transient 
condition in DS and not necessarily imply the occurrence of HT. Considering our data, we 
recommend a careful approach and follow up for children with DS, thyroid hypoplasia and S-
HT, irrespective of the presence or absence of ATA. A recent study demonstrated that the 
distribution plot for TSH had a significant shift of the curve to higher values in subjects 
with DS respect to healthy controls, suggesting that hyperthyrotropinaemia is an innate 
attribute of chromosome 21 trisomy [36]. Moreover, some authors [5, 37-38] have 
proposed that S-HT is probably related to inappropriate secretion of TSH or thyroid 
insensitivity to TSH, rather than to autoimmune thyroiditis.  
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As well as an increase in the probability of thyroid dysfunction we also found an 
increased probability of ATA during the 10-year period. It is important to note that in our EuT 
children, the presence of ATA, mainly TPOab, significantly raised the risk of developing 
thyroid dysfunctions during the long-term follow-up. These data suggest that ATA might 
represent a marker of deteriorating thyroid function unlike 1
st
 year TSH levels that are not 
predicting for future thyroid dysfunction requiring therapy, both in initially EuT and S-
HT subjects with DS. 
The prevalence of ATA in DS children was reported to range from 16% [38] to 39% 
[39]. Moreover, the increased TSH levels were demonstrated to be positively correlated with 
TPOab which were already indicated as a key factor in the follow-up of DS subjects [40]. So, 
our results have confirmed the previously reported findings on the important role of both 
elevated TSH and ATA in the development of HT [10, 14, 16, 17, 39, 41], suggesting that 
children with DS should be tested more frequently than others.  
In the general population it was demonstrated that in children and adolescents with 
both S-HT and autoimmune thyroiditis ATA increased over time [19, 35]. However, the 
progressive increase in TPOab raised the risk of developing HT by 3.5-fold [20], lower than 
data we found in our DS population.  
Up to 10% of patients with autoimmune thyroiditis are ATA negative [42], so thyroid 
ultrasound findings may be important in order to differentiate children with a mild S-HT and 
autoimmune thyroiditis from those with other causes of thyroid dysfunction. Our data support 
the hypothesis that some children with DS may have a persistent mild HT presumably of 
thyroidal origin related to the trisomic state of chromosome 21 [43].  
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Thyroid hormones influence almost all aspects of normal development during 
childhood. They play a crucial role as regulators of neurodevelopment, growth and skeletal 
development, and metabolism [44]. The early diagnosis of thyroid dysfunctions is important 
and pediatricians can often recognize them in their early stages, by maintaining an appropriate 
index of suspicion. Recognition of HT can be very difficult because it has a subtle 
presentation and symptoms overlap with features of DS, including impaired intellectual 
development in young children, decreased linear growth, dry skin and fine hair, excess 
weight, dentition abnormalities, and decreased physical activity [2]. In our DS children with  
thyroid dysfunctions the incidence of replacement therapy was 41%, over the 10-year period. 
The medical treatment of S-HT is a topic of debate [5, 11, 14]; however, almost all patients 
with ATA required treatment [45]. Currently we do not know at which TSH level clinical 
signs and potential adverse effects on lipid profile, cardiac function, and neuropsychiatric 
performance will appear, or whether treatment can prevent them. However, it was 
demonstrated that S-HT, even of many years’ duration, and HT, if appropriately treated 
within a few months, do not impair growth [19]. In the general pediatric population, there is 
no clear evidence of the beneficial effects of L-thyroxine on growth and thyroid volume [21], 
but van Trotsenburg et al. [46] have reported that in children with DS replacement therapy for 
the first 24 months of life probably results in improvements of psychomotor development and 
growth. However, this study was designed to determine the rate of annual thyroid 
dysfunctions in this population, not the appropriateness of treatment.  
In summary, in our study thyroid dysfunctions were relatively common in children 
with DS and, because symptoms might be mistaken for symptoms related to the natural 
course of DS, they may represent a significant health risk if not identified. We suggest that 
DS patients, especially those with EuT or S-TH associated with positive ATA, should be 
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annually monitored to precociously identify thyroid diseases and to begin an adequate 
replacement therapy when proper. 
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 Figures 
Figure 1. Thyroid function: probability of any thyroid dysfunction (excluding C-
HT). 
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Figure 2. Thyroid function: probability of EuT, S-HT, and HT. 
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Figure 3. Anti-thyroid antibodies: probability of positive TGab and TPOab. 
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Figure 4. Anti-thyroid antibodies: changes of TGab and TPOab according to thyroid status 
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Figure 5. Changes of thyroid function according to development of antibodies during follow-up: 1
st
 vs. 10
th
 year.  
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Tables. 
Table 1. Thyroid ultrasound characteristics according to thyroid status at 10
th
 years. 
Thyroid ultrasound characteristics at 10
th
 years 
ATA status at 10
th
 years 
Thyroid status at 10
th
 years 
EuT (73) C-HT (10) HT (30) S-HT (31) HyperT (1) 
Normal (90) 
ATA positive (28/90) 
56 (76.7%) 
10 (13.7%) 
-- 
-- 
17 (56.7%) 
8 (26.7%) 
17 (54.8%) 
10 (32.3%) 
-- 
-- 
Hypoplasia (12) 
ATA positive (1/12) 
Agenesis (6) 
Ectopia (2) 
4 (5.5%) 
-- 
-- 
-- 
2 (20%) 
-- 
6 (60%) 
2 (20%) 
2 (6.6%) 
-- 
-- 
-- 
4 (13.0%) 
1 (3.2%) 
-- 
-- 
-- 
-- 
-- 
-- 
Nodule (1) 
ATA positive (1/1) 
-- 
-- 
-- 
-- 
-- 
-- 
1 (3.2%) 
1 (3.2%) 
-- 
-- 
Diffuse hypoechogenicity (34) 
ATA positive (24/34) 
13 (17.8%) 
13 (17.8%) 
-- 
-- 
11 (36.7%) 
7 (23.3%) 
9 (29.0%) 
3 (9.7%) 
1 (100%) 
1 (100%) 
Data are reported as n. of subjects and % according to thyroid status  
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Table 2. Thyroid autoantibodies (ATA) status according to thyroid ultrasound characteristics during the 10-years follow-up. 
Thyroid ultrasound characteristics Thyroid status ATA status at 10
th
 years 
10
th
 years 10
th
 years TG/TPOab + (24) TPOab + (24) TGab + (6) Negative (81) 
Normal (90) 
 
 
 
 
EuT 
HT 
S-HT 
4 (4.4%) 
2 (2.2%) 
1 (1.1%) 
1 (1.1%) 
20 (22.2%) 
8 (8.9%) 
7 (7.8%) 
5 (5.5%) 
4 (4.4%) 
-- 
-- 
4 (4.4%) 
62 (69.0%) 
46 (51.2%) 
9 (10%) 
7 (7.8%) 
Hypoplasia (10) 
 
 
 
 
EuT 
HT 
S-HT 
-- 
-- 
-- 
-- 
1 (10%) 
-- 
-- 
1 (10%) 
-- 
-- 
-- 
-- 
9 (90%) 
4 (40%) 
2 (20%) 
3 (30%) 
Nodule (1) 
 
 
S-HT 
1 (100%) 
1 (100%) 
-- 
-- 
-- 
-- 
-- 
-- 
Diffuse hypoechogenicity (34) 
 
 
 
 
 
EuT 
HT 
S-HT 
HyperT 
19 (55.9%) 
8 (23.6%) 
7 (20.6%) 
3 (8.8%) 
1 (2.9%) 
3 (8.8%) 
3 (8.8%) 
-- 
-- 
-- 
2 (5.9%) 
2 (5.9%) 
-- 
-- 
-- 
10 (29.4%) 
-- 
4 (11.8%) 
6 (17.6%) 
-- 
Data are reported as n. of subjects and % according to thyroid ultrasound characteristics (patients with C-HT were all negative for ATA so their 
data were excluded from the table) 
